The Impact of the Consciousness Energy Healing Treated Test Formulation on Vital Organs Health Biomarkers

Journal: Journal of Nutritional Dietetics & Probiotics PDF  

Published: 21-Jun-19 Volume: 2 Issue: 2

ISSN: 2460-6624

Authors: Balmer JA, Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC and Jana S

Citation: Balmer JA, et al. The Impact of the Consciousness Energy Healing Treated Test Formulation on Vital Organs Health Biomarkers. J Nutri Diet Probiotics 2019, 2(1): 180017.

  • 219 Views
  • Downloads

Abstract

The study was performed to find out the impact of the Biofield Energy Treated test formulation on the function of vital organs viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media was divided into two parts; one untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, Joy Angevin Balmer, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The Biofield Energy Treated medium (BT-Med) + Biofield Treated test item (UT-TI) group showed 149.3% restoration of cell viability at 1 μg/mL as compared to the UT-Med + UT-TI group in human cardiac fibroblasts cells (HCF). Moreover, the UT-Med + BT-TI and BT-Med + BT-TI groups showed 54.2% (at 0.1 μg/mL) and 43.5% (at 63 μg/mL) restoration of cell viability, respectively in human hepatoma cells (HepG2) compared to untreated. Furthermore, 58.3% restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by UTMed + BT-TI group at 0.1 μg/mL compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 92.4%, 72.1%, and 87.4% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively at 50 μg/mL in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 64.7% (at 25 μg/mL) and 87.9% (at 50 μg/mL) in the BT-Med + BT-TI group in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 163% and 80.6% in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively at 0.1 μg/mL compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 89.3% and 60.4% at 1 μg/mL in the BT-Med + UT-TI and BTMed + BT-TI groups, respectively compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 61.1% (at 1 μg/mL) and 43.5% (at 63 μg/mL) in the BT-Med + BT-TI and BT-Med + UT-TI groups, respectively compared to untreated in A549 cells. Serotonin level was significantly increased by 32.5% and 34.2% in the BT-Med + BT-TI group at 10 and 63 μg/mL, respectively as compared to untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 174.4% (at 10 μg/mL), 212% (at 1 μg/mL), and 196.1% (at 0.01 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Treated test formulation significantly improved the bones, heart, liver, lungs, and brain functional enzyme biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, liver cancer, Wilson disease, hemochromatosis, pneumonia, asthma, chronic bronchitis, emphysema, osteoporosis, cystic fibrosis, etc.

Conclusion

The study results showed that the test formulation was found as safe and non-toxic based on the cell viability assay in six tested cells. The treatment group like BT-Med + BT-TI showed 149% restoration of cell viability at 1 μg/mL in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the UT-Med + BT-TI group showed 54.2% restoration of cell viability at 0.1 μg/mL in human hepatoma cells (HepG2) compared to the untreated group. Additionally, the UT-Med + BT-TI group showed 58.3% (at 0.1 μg/mL) restoration of cell viability in adenocarcinomic human alveolar basal epithelial cells (A549) compared to the untreated group. Alkaline phosphatase (ALP) activity was significantly increased by 92.4% in the UT-Med + BT TI group at 50 μg/mL in human bone osteosarcoma cells (MG-63). Moreover, ALP activity was significantly increased by 87.9% at 50 μg/mL in the BT-Med + BT-TI group than untreated group. The percent protection of HCF cells (decreased of LDH activity) was significantly increased by 163% (at 0.1μg/mL) in the BT-Med + UT-TI group compared to the untreated group in HCF cells. The percent protection of HepG2 cells (decreased of ALT activity) was significantly increased by 89.3% (at 1 μg/mL) in the BT-Med + UT-TI group compared to the untreated group in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 61.1% in the BT-Med + BT-TI group at 1 μg/mL compared to the untreated group in A549 cells. The serotonin level was significantly increased by 34.2% at 63 μg/mL in the BT-Med + BT-TI group compared to the untreated group in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptors (VDRs) level was significantly increased by 174.4% (at 10 μg/mL), 212% (at 1 μg/mL), and 196.1% (at 0.01 μg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively as compared to the untreated in MG-63 cells. In conclusion, the Biofield Energy Treatment significantly improved heart, liver, bones, neuronal, and lungs functional enzyme biomarkers and also protected cardiomyocyte, hepatocyte, osteocytes, pneumocyte, and nerve cells from oxidative damage induced by tert-butyl hydroperoxide (t-BHP). Thus, results suggested that Biofield Energy Treatment can be used as a complementary and alternative treatment for the prevention of various types of cardiac disorders (peripheral artery disease, high blood pressure, congenital heart disease, stroke, congestive heart failure, rheumatic heart disease, carditis, valvular heart disease, thromboembolic disease, and venous thrombosis, etc.), hepatic disorders (cirrhosis, Wilson disease, liver cancer, hemochromatosis), and lungs disorders (Asthma, Emphysema, Chronic bronchitis, Pneumonia, Cystic fibrosis). Further, it can be useful to improve cell-to-cell messaging, normal cell growth and differentiation, cell cycling and proliferation, neurotransmission, skin health, hormonal balance, immune and cardiovascular functions. Moreover, it can also be utilized in organ transplants (i.e., liver, kidney, and heart transplants), aging, hormonal imbalance and various inflammatory and immune-related disease conditions like Alzheimer’s Disease (AD), Dermatitis, Asthma, Ulcerative Colitis (UC), Hashimoto Thyroiditis, Pernicious Anemia, Sjogren Syndrome, Aplastic Anemia, Multiple Sclerosis, Hepatitis, Graves’ Disease, Irritable Bowel Syndrome (IBS), Dermatomyositis, Diabetes, Myasthenia Gravis, Atherosclerosis, Parkinson’s Disease, Systemic etc. to Lupus Erythematosus (SLE), stress, improve overall health and Quality of Life.